ToxoTech AB
Developing precision-engineered next-generation botulinum neurotoxin therapeutics for neurological disorders.
Overview
- 1–4
- Employees
- 400–499K SEK
- Revenue
- 2019
- Founded
Key Decision Makers
Jonathan Ilicki
Board Member
Geoffrey Masuyer
Founder, CEO
Pål Stenmark
Founder, Vice-CEO
Sara Persson Košenina
Principal Scientist
Description
ToxoTech is a Stockholm-based biopharmaceutical company founded in 2020 as a spin-out from Stockholm University. The organization specializes in advancing the science behind next-generation botulinum neurotoxin (BoNT) therapeutics. Their core technology focuses on engineering improved toxin-receptor...